# Jaypirca (pirtobrutinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pirtobrutinib

> The FDA approved Jaypirca (pirtobrutinib), sponsored by ELI LILLY & Co (LLY), on January 27, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Jaypirca (pirtobrutinib) FDA approved?

Yes. The FDA approved Jaypirca (pirtobrutinib), sponsored by ELI LILLY & Co (LLY), on January 27, 2023. FDA novel drug approvals: "Jaypirca | pirtobrutinib | 1/27/2023 | To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/pirtobrutinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/pirtobrutinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Jaypirca (pirtobrutinib) |
| Codes | LOXO305, LOXO-305, LY3527727 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia), Lymphoma, Non-Hodgkin, [Lymphoma, Mantle-Cell](https://sec-api.dev/indications/lymphoma-mantle-cell) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### January 27, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Jaypirca | pirtobrutinib | 1/27/2023 | To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216059 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230127, review_priority PRIORITY; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22

### December 1, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216059 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20231201, review_priority PRIORITY; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-27, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001651308-25-000029): "•Anticipate initiation of Phase 3 head-to-head trial against noncovalent BTK inhibitor pirtobrutinib in R/R CLL in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm
- SEC Form 10-K (accession 0001651308-25-000031): "We plan to initiate a Phase 3 head-to-head trial in 2025 against pirtobrutinib, consistent with our strategy to develop medicines that have potential to meaningfully improve upon the current practice of care." https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/bgne-20241231.htm

### July 11, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." https://clinicaltrials.gov/study/NCT05023980

### December 2, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216059 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251202, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22

### September 25, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." https://clinicaltrials.gov/study/NCT05023980?tab=results

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04965493 (A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT04965493

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04965493 (A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT04965493

### October 2, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216059 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20261002, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05254743 (A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT05254743

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05254743 (A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT05254743

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lymphoma, Mantle-Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT04662255

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lymphoma, Mantle-Cell.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04662255 (Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT04662255

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06588478 (A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT06588478

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06588478 (A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Loxo Oncology, Inc.." https://clinicaltrials.gov/study/NCT06588478

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07162181 (Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07162181

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07162181 (Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07162181

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib) (ABBV)
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib) (MRK)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pirtobrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Jaypirca (pirtobrutinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pirtobrutinib

```bibtex
@misc{secapidev_pdufa_pirtobrutinib_20261116,
  title        = {Jaypirca (pirtobrutinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pirtobrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pirtobrutinib_20261116","title":"Jaypirca (pirtobrutinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pirtobrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
